Matrix metalloproteinase target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 51-69

  Pirard, Bernard ^a,b   Matter, Hans ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; BINDING SITE; CHEMOMETRIC ANALYSIS; CONSENSUS PRINCIPAL COMPONENT ANALYSIS; CRYSTAL STRUCTURE; ENZYME STRUCTURE; FORCE; MOLECULAR INTERACTION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; STRUCTURE ANALYSIS;

ADAM PROTEINS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MATRIX METALLOPROTEINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PRINCIPAL COMPONENT ANALYSIS; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30444435765     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050363f     Document Type: Article

References (120)

1. Klebe, G., Ed. Virtual Screening: An Alternative or Complement to High Throughput Screening; Kluwer/Escom: Dordrecht, The Netherlands, 2000.
2. Schneider, G.; Böhm, H.-J. Virtual screening and fast automated docking methods. Drug Discovery Today 2002, 7, 64-70.
3. Böhm, H.-J., Schneider, G., Eds. Virtual Screening for Bioactive Molecules; Wiley-VCH: Weinheim, Germany, 2000.
4. Klebe, G. Recent developments in structure-based drug design. J. Mol. Med. 2000, 78, 269-281.
5. Murcko, M. A.; Caron, P. R.; Charifson, P. S. Structure-based drug design. Annu. Rep. Med. Chem. 1999, 34, 297-306.
6. Gane, P. J.; Dean, P. M. Recent advances in structure-based rational drug design. Curr. Opin. Struct. Biol. 2000, 10, 401-404.
7. Kubinyi, H. Structure-based design of enzyme inhibitors and receptor ligands. Curr. Opin. Drug Discovery Dev. 1998, 1, 4-15.
8. Böhm, H.-J.; Stahl, M. Structure-based library design: molecular modelling merges with combinatorial chemistry. Curr. Opin. Chem. Biol. 2000, 4, 283-286.
9. Kornberg, A. The two cultures. Chemistry and biology. Biochemistry 1987, 26, 6888-6891.
10. Wess, G.; Urmann, M.; Sickenberger, B. Medicinal chemistry: challenges and opportunities. Angew. Chem., Int. Ed. 2001, 40, 3341-3350.
11. Caron, P. R.; Mullican, M. D.; Mashal, R. D.; Wilson, K. P.; Su, M. S.; Murcko, M. A. Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol. 2001, 5, 464-470.
12. Lehman, J.; Baxter, A.; Brown, D.; Connolly, P.; Geysin, M.; Hayes, M.; Howard, R.; Knowles, J.; Lee, M.; Lyall, A.; et al. Systematization of research. Nature 1996, 384 (Suppl. 7), 5.
13. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
14. Ajay; Bemis, G. W.; Murcko, M. A. Designing libraries with CNS activity. J. Med. Chem. 1999, 42, 4942-4951.
15. Blundell, T. L.; Jhoti, H.; Abell, C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. 2002, 1, 45-54.
16. (a) Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
17. (b) Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.: Wade, R. C. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J. Med. Chem. 1989, 32, 1083-1094.
18. (c) Wade, R. C.; Clerk, K. J.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 1. Ligand probe groups with the ability to form two hydrogen bonds. J. Med. Chem. 1993, 36, 140-147.
19. (d) Wade, R. C.; Goodford, P. J. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. J. Med. Chem. 1993, 36, 148-156.
20. GRID, version 19; Molecular Discovery Ltd. (West Way House, Elms Parade): Oxford, U.K., 2001.
21. (a) Wold, S.; Esbensen, K.; Geladi, P. Principal component analysis. Chemom. Intell. Lab. Syst. 1987, 2, 37-52.
22. (b) Dillon, W. R.; Goldstein, M. Multivariate Analysis: Methods and Applications; Wiley: New York, 1984.
23. (c) Malinowski, E. R.; Howery, D. G. Factor Analysis in Chemistry; Wiley: New York, 1980.
24. (d) Stahle, L.; Wold, S. Multivariate Data Analysis and Experimental Design in Biomedical Research. In Progress in Medicinal Chemistry Ellis, G. P., West, G. B., Eds.; Elsevier: Amsterdam, The Netherlands, 1988; pp 292-338.
25. (e) Wold, S.; Albano, C.; Dunn, W. J., III; Edlund, U.; Esbensen, K.; Geladi, P.; Hellberg, S.; Johanson, E.; Lindberg, W.; Sjöström, M. Multivariate Data Analysis in Chemistry. In Chemometrics: Mathematics and Statistics in Chemistry; Kowalski, B. R., Ed.; NATO, ISI Series C 138; D. Reidel Publ. Co.; Dordrecht, The Netherlands, 1984; pp 17-96.
26. Cruciani, G.; Goodford, P. J. A search for specificity in DNA-drug interactions. J. Mol. Graphics 1994, 12, 116-129.
27. Pastor, M.; Cruciani, G. A novel strategy for improving ligand selectivity in receptor-based drug design. J. Med. Chem. 1995, 38, 4637-4647.
28. Matter, H.; Schwab, W. Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins. J. Med. Chem. 1999, 42, 4506-4523.
29. Matter, H.; Schwab, W. A View on Affinity and Selectivity of Nonpeptidic Matrix Metalloproteinase Inhibitors from the Perspective of Ligands and Target. In Molecular Modeling and Prediction of Bioactivity; Gundertofte, K., Jørgensen, F. S., Eds.; Kluwer: New York, 2000; pp 123-128.
30. Filipponi, E.; Cecchetti, V.; Tabarrini, O.; Bonelli, D.; Fravolini, A. Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands. J. Comput.-Aided Mol. Des. 2000, 14, 277-291.
31. Kastenholz, M. A.; Pastor, M.; Cruciani, G.; Haaksma, E. E. J.: Fox, T. GRID/CPCA: a new computational tool to design selective ligands. J. Med. Chem. 2000, 43, 3033-3044.
32. Westerhuis, J. A.; Kourti, T.; Macgregor, J. F. Analysis of multiblock and hierarchical PCA and PLS models. J. Chemom. 1998, 12, 301-321.
33. Matter, H.; Defossa, E.; Heinelt, U.; Naumann, T.; Schreuder, H.; Wildgoose, P. Combining Structure-based Design and 3D-QSAR towards the Discovery of Non-chiral, Potent and Selective Factor Xa Inhibitors. In Rational Approaches to Drug Design, Proceedings of the 13th European Symposium on Quantitative Structure-Activity Relationships; Höltje, H.-D., Sippl, W., Eds.; Prous Science: Barcelona, Spain, 2001; pp 177-185.
34. Ridderström, M.; Zamora, I.; Fjellström, O.; Andersson, T. B. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J. Med. Chem. 2001, 44, 4072-4081.
35. Naumann, T.; Matter, H. Structural classification of protein kinases using 3D molecular-interaction field analysis of their ligand binding sites: target family landscapes. J. Med. Chem. 2002, 45, 2366-2378.
36. Terp, G. E.; Cruciani, G.; Christensen, I. T.; Jorgensen, F. S. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem. 2002, 45, 2675-2684.
37. Reiter, L. A.; Rizzi, J. P.; Pandit, J.; Lasut, M. J.; McGahee, S. M.; Parikh, V. D.; Blake, J. F.; Danel, D. E.; Laird, E. R.; Lopez-Anaya, A.; Lopresti-Morrow, L. L.; Mansour, M. N.; Martinelli, G. C.; Mitchell, P. G.; Owens, B. S.; Pauly, T. A.; Reeves, L. M.; Schulte, G. K.; Yocum, S. A. Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket. Bioorg. Med. Chem. Lett. 1999, 9, 127-132.
38. Finzel, B. C.; Baldwin, E. T.; Bryant, G. L., Jr.; Hess, G. F.; Wilks, J. W.; Trepod, C. M.; Mott, J. E.; Marshall, V. P.; Petzold, G. L.; Poorman, R. A.; O'Sullivan, T. J.; Schostarez, H. J.; Mitchell, M. A. Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci. 1998, 7, 2118-2126.
39. Lukacova, V.; Zhang, Y.; Mackov, M.; Baricic, P.; Raha, S.; Calva, J. A.; Balaz, S. Similarity of binding sites of human matrix metalloproteinases. J. Biol. Chem. 2004, 279, 14194-14200.
40. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
41. Gohlke, H.; Hendlich, M.; Klebe, G. Predicting binding modes, binding affinities and "hot spots" for protein-ligand complexes using a knowledge-based scoring function. Perspect. Drug Discovery Des. 2000, 20, 115-144.
42. (a) RCSB Protein Data Bank, from the Research Collaborator for Structural Bioinformatics: http://www.rcsb.org/pdb/index.html.
43. (b) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The protein data bank. Nucleic Acids Res. 2000, 28, 235-242.
44. Hendlich, M. Databases for protein-ligand complexes. Acta Crystallogr., Sect. D 1998, 54, 1178-1182.
45. Gohlke, H.; Klebe, G. Statistical potentials and scoring functions applied to protein-ligand binding. Curr. Opin. Struct. Biol. 2001, 11, 231-235.
46. (a) Mügge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
47. (b) Mügge, I.; Martin, Y. C.; Hajduk, P. J.; Fesik, S. W. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. J. Med. Chem. 1999, 42, 2498-2503.
48. (a) Mitchell, J. B. O.; Laskowski, R. A.; Alex, A.; Thornton, J. M. BLEEP-Potential of mean force describing protein-ligand interactions. I. Generating potentials. J. Comput. Chem. 1999, 20, 1165-1176.
49. (b) Mitchell, J. B. O.; Laskowski, R. A.; Alex, A.; Forster, M. J.; Thornton. J. M. BLEEP-Potential of mean force describing protein-ligand interactions. 11. Calculation of binding energies and comparison with experimental data. J. Comput. Chem. 1999, 20, 1177-1185.
50. Sotriffer, C. A.; Gohlke, H.; Klebe, G. Docking into knowledge-based potential fields: a comparative evaluation of DrugScore. J. Med. Chem. 2002, 45, 1967-1970.
51. Matter, H.; Schudok, M. Recent advances in the design of matrix metalloproteinase inhibitors. Curr. Opin. Drug Discovery Dev. 2004, 7, 513-535.
52. (a) Woessner, J. F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991, 5, 2145-2154.
53. (b) Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 1993, 4, 197-250.
54. (c) Murphy, G.; Docherty, A. J. P. The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell Mol. Biol. 1992, 7, 120-125.
55. (d) Matrisian, L. M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990, 6, 121-125.
56. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 2001, 8, 425-474.
57. (a) Goldring, M. B. Degradation of Articular Cartilage in Culture: Regulatory Factors. In Joint Cartilage Degradation; Woessner, J. F., Howell, D. S., Eds.; Dekker: New York 1993; pp 281-346.
58. (b) Willenbrock, F.; Murphy, G. Structure-function relationships in the tissue inhibitors of metalloproteinases. Am. J. Respir. Crit. Care Med. 1994, 150, 5165-5170.
59. (c) Murphy, G.; Willenbrock, F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 1995, 248, 496-510.
60. Kleiner, D. E.; Stetler-Stevenson, W. G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol. 1999, 43 (Suppl.), S42-S51.
61. Lohmander, L. S.; Hoerrner, L. A.; Lark, M. W. Metalloproteinases. tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 1993, 36, 181-189.
62. Murphy, G.; Hembry, R. M. Proteinases in rheumatoid arthritis. J. Rheumatol. 1992, 79, 61-64.
63. Peress, N.; Perillo, E.; Zucker, S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54, 16-22.
64. Bode, W.; Reinemer, P.; Huber, R.; Kleine, T.; Schmierer, S.; Tschesche, H. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 1994, 13, 1263-1269.
65. Murphy, G. J.; Murphy, G.; Reynolds, J. J. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett. 1991, 89, 4-7.
66. Pendas, A. M.; Knauper, V.; Puente, X. S.; Llano, E.; Mattei, M. G.; Apte, S.; Murphy, G.; Lopez Otin, C. Identification and characterization of a novel human matrix metalloproteinase with unique structural features, chromosomal location, and tissue distribution. J. Biol. Chem. 1997, 272, 4281-4286.
67. (a) Borkakoti, N. Structural studies on matrix metalloproteinases. J. Mol. Med. 2000, 78, 261-268.
68. (b) Borkakoti, N. The structural basis of matrix metalloproteinase inhibition. Curr. Opin. Drug Discovery 1999, 2, 449-462.
69. Li, J.; Brick, P.; O'Hare, M. C.; Skarzynski, T.; Lloyd, L. F.; Curry, V. A.; Clark, I. M.; Bigg, H. F.; Hazleman, B. L.; Cawston, T. E.; Blow, D. M. Structure of the full length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four bladed beta propeller. Structure 1995, 3, 541-549.
70. Massova, I.; Kotra, L. P.; Fridman, R.; Mobashery, S. Matrix metalloproteinases: structures, evolution and diversification. FASEB J. 1998, 12, 1075-1095.
71. Frye, S. V. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic area. Chem. Biol. 1999, 6, R3-R7.
72. Stams, T.; Spurlino, J. C.; Smith, D. L.; Wahl, R. C.; Ho, T. F.; Qoronfleh, M. W.; Banks, T. M.; Rubin, B. Structure of human neutrophil collagenase reveals large S1′ specificity pocket. Nat. Struct. Biol. 1994, 1, 119-23.
73. Welch, A. R.; Holman, C. M.; Huber, M.; Brenner, M. C.; Browner, M. F.; Van Wart, H. E. Understanding the P1′ specificity of the matrix metalloproteinases: effect of S1′ pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996, 35, 10103-10109.
74. Matter, H.; Schwab, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Schudok, M.; Thorwart, W.; Schreuder, H.; Brachvogel, V.; Loenze, P.; Weithmann, K. U. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. J. Med. Chem. 1999, 42, 1908-1920.
75. Browner, M. F.; Smith, W. W.; Castelhano, A. L. Crystal structures of matrilysin-inhibitor complexes. Biochemistry 1995, 34, 6602-10.
76. Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 1999, 6, 217-221.
77. Moy, F. J.; Chanda, P. K.; Chen, J.; Cosmi, S.; Edris, W.; Levin, J. I.; Rush, T. S.; Wilhelm, J.; Powers, R. Impact of mobility on structure-based drug design for the MMPs. J. Am. Chem. Soc. 2002, 124, 12658-12659.
78. Källblad, P.; Todorov, N. P.; Willems, H. M. G.; Alberts, I. L. Receptor flexibility in the in silico screening of reagents in the S1′ pocket of human collagenases. J. Med. Chem. 2004, 47, 2761-2767.
79. Steele, D. L.; El-Kabbani, O.; Dunten, P.; Windsor, L. J.; Kammlott, R. U.; Crowther, R. L.; Michoud, C.; Engler, J. A.; Birktoft, J. J. Expression, characterization and structure determination of an active site mutant (Glu202-Gln) of mini-stromelysin-1. Protein Eng. 2000, 13, 397-405.
80. GOLPE. version 4.5.; Multivariate Infometric Analysis, SrI (Viale die Castagni, 16): Perugia, Italy, 1999.
81. Nar, H.; Werle, K.; Bauer, M. M. T.; Dollinger, H.; Jung, B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J. Mol. Biol. 2001, 312, 743-751.
82. Matter, H.; Will, D. W.; Nazaré, M.; Schreuder, H.; Laux, V.; Wehner, V. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral Pl substituents: combining X-ray crystallography, 3D-QSAR and tailored scoring functions. J. Med. Chem. 2005, 48, 3920-3312.
83. Bergner, A.; Günther, J.; Hendlich, M.; Klebe, G.; Verdonk, M. Use of Relibase for retrieving complex three-dimensional interaction patterns including crystallographic packing effects. Biopolymers 2002, 61, 99-110.
84. Borkakoti, N.; Winkler, F. K.; Williams, D. H.; D'Arcy, A.; Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat. Struct. Biol. 1994, 1, 106-110.
85. Natchus, M. G.; Cheng, M.; Wahl, C. T.; Pikul, S.; Almstead, N. G.; Bradley, R. S.; Taiwo, Y. O.; Mieling, G. E.; Dunaway, C. M.; Snider, C. E.; Mciver, J. M.; Barnett, B. L.; Mcphail, S. J.; Anastasio, M. B.; De, B. Design and synthesis of conformationally-constrained MMP inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 2077-2080.
86. Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
87. Stockman, B. J.; Waldon, D. J.; Gates, J. A.; Scahill, T. A.; Kloosterman, D. A.; Mizsak, S. A.; Jacobsen, E. J.; Belonga, K. L.; Mitchell. M. A.; Mao, B.; Petke, J. D.; Goodman, L.; Powers, E. A.; Ledbetter, S. R.; Kaytes, P. S.; Vogeli, G.; Marshall, V. P.; Petzold, G. L.; Poonnan, R. A. Solution structures of stromelysin complexed to thiadiazole. Protein Sci. 1998, 7, 2281-2286.
88. Botos, I.; Meyer, E.; Swanson, S. M.; Lemaitre, V.; Eeckhout, Y.; Meyer, E. F. Structure of recombinant mouse collagenase-3 (MMP-13). J. Mol. Biol. 1999, 292, 837-844.
89. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776.
90. Brown, S.; Meroueh, S. O.; Fridman, R.; Mobashery, S. Quest for selectivity in inhibition of matrix metalloproteinases. Curr. Top. Med. Chem. 2004, 4, 1227-1238.
91. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295, 2387-2392.
92. Hanessian, S.; Bourbouz, S.; Boudon, A.; Tucker, G. C.; Peyroulan, D.; Picking the S1, S1′ and S2′ pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1691-1696.
93. Hanessian, S.; Moitessier, N.; Gauchet, C.; Viau, M. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S1, S1′, and S2′ pockets. J. Med. Chem. 2001, 44, 3066-3073.
94. Hanessian, S.; MacKay, D. B.; Moitessier, N. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S1 pocket by conformationally constrained inhibitors. J. Med. Chem. 2001, 44, 3074-3082.
95. Vassiliou, S.; Mucha, A.; Cuniasse, P.; Georgiadis, D.; Lucet-Levannier, K.; Beau, P.; Kannan, R.; Murphy, G.; Knäuper, V.; Rio, M. C.; Basset, P.; Yiotakis, A.; Dive, V. Phosphinic pseudotripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. J. Med. Chem. 1999, 42, 2610-2620.
96. Gall, A. L.; Ruff, M.; Kannan, R.; Cuniasse, P.; Yiotakis, A.; Dive, V.; Rio, M. C.; Basset, P.; Moras, D. Crystal structure of the stromelysin-3 (MMP-11 ) catalytic domain complexed with a phosphinic inhibitor mimicking the transition state. J. Mol. Biol. 2001, 107, 577-586.
97. Mucha, A.; Cuniasse, P.; Kannan, R.; Beau, F., Yiotakis, A.; Basset, P.; Dive, V. Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently synthetic substrates containing unusual amino acids in their P1′ positions. J. Biol. Chem. 1998, 273, 2763-2768.
98. Matter, H.; Schudok, M.; Schwab, W.; Thorwart, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Weithmann, K. U.; Wollmann, T. Tetrahydroisoquoinoline-3-carboxylate based matrix metalloproteinase inhibitors: design, synthesis and structure-activity relationship. Bioorg. Med. Chem. 2002, 10, 3529-3544.
99. Cherney, R. J.; Wang, L.; Meyer, D. T.; Xue, C. B.; Wasserman, Z. R.; Hardman, K. D.; Welch, P. K.; Covington, M. B.; Copeland, R. A.; Arner, E. C.; DeGrado, W. F.; Decicco, C. P. Macrocyclic amino carboxylates as selective MMP-8 inhibitors. J. Med. Chem. 1998, 41, 1749-1751.
100. Cherney, R. J.; Decicco, C. P.; Nelson, C. R.; Wan, L.; Meyer, D. T.; Hardman, K. D.; Copeland, R. A.; Arner, E. C. Potent carboxylate inhibitors of stromelysin containing P2′ piperazic acids and P1′ biaryl moieties. Bioorg. Med. Chem. Lett. 1997, 7, 1757-1762.
101. Betz, M.; Huxley, P.; Davies, S.; Mushtaq, Y.; Pieper, M.; Tschesche, H.; Bode, W.; Gomis-Ruth, F. 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. J. Biochem. 1997, 247, 356-363.
102. Tamura, Y.; Watanabe, F., Nakatani, T.; Yasui, K.; Fuji, M.; Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.; Sugita, K.; Ohtani, M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 1998, 41, 640-649.
103. Foley, L. H.; Palermo, R.; Dunten, P.; Wang, P. Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 969-972.
104. Dunten, P.; Kammlott, U.; Crowther, R.; Levin, W.; Foley, L. H.; Wang, P.; Palermo, R. X-ray structure of a novel matrix metallo-proteinase inhibitor complexed to stromelysin. Protein Sci. 2001, 10, 923-926.
105. Wada, C. K.; Holmes, J. H.; Curtin, M. L.; Dai, Y.; Florjanic, A. S.; Garland, R. B.; Guo, Y.; Heyman, H. R.; Stacey, J. R.; Steinmn, D. H.; Albert, D. H.; Bouska, J. J.; Elmore, I. N.; Goodfellow, C. L.; Marcotte, P. A.; Tapang, P.; Morgan, D. W.; Michaelides, M. R.; Davidsen, S. K. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem. 2002, 45, 219-232.
106. Robinson, R. P.; Laird, E. R.; Donahue, K. M.; Lopresti-Morrow, L. L.; Mitchell, P. G.; Reese, M. R.; Reeves, L. M.; Rouch, A. I.; Stam, E. J.; Yocum, S. A. Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxamides as potent matrix metalloproteinase-13 inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1211-1213.
107. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klingler, O.; Schlotte, V.; Weithmann, K. U.; Wendt, K. U. Structural basis for highly selective inhibition of MMP-13. Chem. Biol. 2005, 12, 181-189.
108. SYBYL Molecular Modeling Package, version. 6.6; Tripos, St. Louis, MO, 1999.
109. (a) Halgren, T. Maximally diagonal force constants in dependent angle-bending coordinates. II. Implications for the design of empirical force fields. J. Am. Chem. Soc. 1990, 112, 4710-4723.
110. (b) Halgren, T. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20, 720-729.
111. Relibase+, version L, available from Cambridge Crystallographic Data Center (http://www.ccdc.cam.ac.uk/).
112. Web site at Wayne State University, Detroit, MI: http://sun2.science. wayne.edu/~somgroup.
113. MOE. version 2001.01, available from Chemical Computing Group, Inc. (http://www.chemcomp.com/).
114. Dhanaraj, V.; Williams, M. G.; Ye, Q.-Z.; Molina, F.; Johnson, L. L.; Ortwine, D. F.; Pavlovsky, A.; Rubin, J. R.; Skeean, R. W.; White, A. D.; Humblet, C.; Hupe, D. J.; Blundell, T. L. X-ray structure of gelatinase A catalytic domain complexed with a hydroxamate inhibitor. Croat. Chem. Acta 1999, 72, 575-591.
115. Jacobson, M.; Sali, A. Comparative protein structure modeling and its applications to drug discovery. Annu. Rep. Med. Chem. 2004, 39, 259-276
116. (a) Blundell, T. L.; Carney, D. P.; Gardner, S.; Hayes, F. R. F.; Howlin, B.; Hubbard, T. J. P.; Overington, J. P.; Singh, D. A.; Sibanda, B. L.; Sutcliffe, M. J. Knowledge-based protein modeling and design. Eur. J. Biochem. 1988, 172, 513-520.
117. (b) Sutcliffe, M. J.; Haneef, I.; Carney, D. P.; Blundell, T. L. Knowledge-based modeling of homologous proteins. Part I: three-dimensional frameworks derived from the simultaneous superposition of multiple structures. Protein Eng. 1987, 1, 377-384.
118. (c) Sutcliffe, M. J.; Hayes, F. R. F.; Blundell, T. L. Knowledge based modeling of homologous proteins. Part II: Rules for the conformations of substituted side chains. Protein Eng. 1987, 1, 385-392.
119. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quantum Struct.-Act. Relat. 1993, 12, 9-20.
120. McMartin, C.; Bohacek, R. S. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.